-
1
-
-
0035145462
-
Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2
-
Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558-566.
-
(2001)
J Pharmacol Exp Ther
, vol.296
, pp. 558-566
-
-
Riendeau, D.1
Percival, M.D.2
Brideau, C.3
Charleson, S.4
Dube, D.5
Ethier, D.6
-
2
-
-
0003111606
-
The history of anti-inflammatory drugs and their mechanism of action
-
Bazan N, Botting J, Vane J (eds.). London: Kluwer Academic and William Harvey Press
-
Vane JR, Botting RM: The history of anti-inflammatory drugs and their mechanism of action, in: Bazan N, Botting J, Vane J (eds.), New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules. London: Kluwer Academic and William Harvey Press, 1996;1-12.
-
(1996)
New Targets in Inflammation: Inhibitors of COX-2 or Adhesion Molecules
, pp. 1-12
-
-
Vane, J.R.1
Botting, R.M.2
-
3
-
-
0029040041
-
Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs
-
Smith WL, DeWitt DL: Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs. Sem Nephrol 1995;15:179-194.
-
(1995)
Sem Nephrol
, vol.15
, pp. 179-194
-
-
Smith, W.L.1
DeWitt, D.L.2
-
4
-
-
0031113915
-
COX-II inhibitors - A new generation of safer NSAIDs?
-
Donnelly MT, Hawkey CJ: COX-II inhibitors - a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997;11:227-236.
-
(1997)
Aliment Pharmacol Ther
, vol.11
, pp. 227-236
-
-
Donnelly, M.T.1
Hawkey, C.J.2
-
5
-
-
0030911815
-
Cyclooxygenase isoenzymes: How recent findings affect thinking about nonsteroidal anti-inflammatory drugs
-
Jouzeau J-Y, Terlain B, Abid A, Nedelec E, Netter P: Cyclooxygenase isoenzymes: how recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 1997;53:563-582.
-
(1997)
Drugs
, vol.53
, pp. 563-582
-
-
Jouzeau, J.-Y.1
Terlain, B.2
Abid, A.3
Nedelec, E.4
Netter, P.5
-
6
-
-
0027146692
-
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase
-
Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR: Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994;90:11693-11697.
-
(1994)
Proc Natl Acad Sci USA
, vol.90
, pp. 11693-11697
-
-
Mitchell, J.A.1
Akarasereenont, P.2
Thiemermann, C.3
Flower, R.J.4
Vane, J.R.5
-
7
-
-
0034707105
-
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
-
Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
-
(2000)
N Engl J Med
, vol.343
, pp. 1520-1528
-
-
Bombardier, C.1
Laine, L.2
Reicin, A.3
Shapiro, D.4
Burgos-Vargas, R.5
Davis, B.6
-
8
-
-
0033601079
-
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs
-
Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-1933.
-
(1999)
JAMA
, vol.282
, pp. 1929-1933
-
-
Langman, M.J.1
Jensen, D.M.2
Watson, D.J.3
Harper, S.E.4
Zhao, P.L.5
Quan, H.6
-
9
-
-
0346906525
-
Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers
-
Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, et al: Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos 2003;43:268-276.
-
(2003)
Drug Metab Dispos
, vol.43
, pp. 268-276
-
-
Rodrigues, A.D.1
Halpin, R.A.2
Geer, L.A.3
Cui, D.4
Woolf, E.J.5
Matthews, C.Z.6
-
10
-
-
0034836419
-
Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers
-
Agrawal NGB, Porras AG, Matthews CZ, Woolf EJ, Miller JL, Mukhopadhyay S, et al: Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001;41:1106-1110.
-
(2001)
J Clin Pharmacol
, vol.41
, pp. 1106-1110
-
-
Agrawal, N.G.B.1
Porras, A.G.2
Matthews, C.Z.3
Woolf, E.J.4
Miller, J.L.5
Mukhopadhyay, S.6
-
11
-
-
0037372154
-
Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man
-
Agrawal NGB, Porras AG, Matthews CZ, Rose MJ, Woolf EJ, Musser BJ, et al: Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man. J Clin Pharmacol 2003;43:268-276.
-
(2003)
J Clin Pharmacol
, vol.43
, pp. 268-276
-
-
Agrawal, N.G.B.1
Porras, A.G.2
Matthews, C.Z.3
Rose, M.J.4
Woolf, E.J.5
Musser, B.J.6
-
12
-
-
0035946023
-
High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluorescence detection
-
Matthews CZ, Woolf EJ, Lin L, Fang W, Hsieh J, Ha S, et al: High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluorescence detection. J Chromatogr B 2001;751:237-246.
-
(2001)
J Chromatogr B
, vol.751
, pp. 237-246
-
-
Matthews, C.Z.1
Woolf, E.J.2
Lin, L.3
Fang, W.4
Hsieh, J.5
Ha, S.6
-
13
-
-
0000568066
-
A simplex optimization program
-
Yeh KC, Remphrey K: A simplex optimization program. Pharm Res 1990;7:S244.
-
(1990)
Pharm Res
, vol.7
-
-
Yeh, K.C.1
Remphrey, K.2
-
14
-
-
0036733531
-
Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis
-
Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, et al: Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology 2002;41:1052-1061.
-
(2002)
Rheumatology
, vol.41
, pp. 1052-1061
-
-
Gottesdiener, K.1
Schnitzer, T.2
Fisher, C.3
Bockow, B.4
Markenson, J.5
Ko, A.6
-
15
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
-
(1976)
Nephron
, vol.16
, pp. 31-41
-
-
Cockcroft, D.W.1
Gault, M.H.2
-
16
-
-
0035938410
-
In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)
-
Chauret N, Yergey JA, Brideau C, Friesen RW, Mancini J, Riendeau D, et al: In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 2001;11:1059-1062.
-
(2001)
Bioorg Med Chem Lett
, vol.11
, pp. 1059-1062
-
-
Chauret, N.1
Yergey, J.A.2
Brideau, C.3
Friesen, R.W.4
Mancini, J.5
Riendeau, D.6
-
17
-
-
33751335393
-
Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: Implication for renal function
-
Komhoff M, Grone HJ, Klein T, Seyberth HW, Nusing RM: Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol Renal Physiol 1997;272:F460-F468.
-
(1997)
Am J Physiol Renal Physiol
, vol.272
-
-
Komhoff, M.1
Grone, H.J.2
Klein, T.3
Seyberth, H.W.4
Nusing, R.M.5
-
18
-
-
0031679914
-
Interspecies differences in renal localization of cyclooxygenase isoforms: Implications in nonsteroidal antiinflammatory drug-related nephrotoxicity
-
Khan KNM, Venturini CM, Bunch RT, Brassard JA, Koki AT, Morris DL, et al: Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity. Toxicol Pathol 1998;26:612-620.
-
(1998)
Toxicol Pathol
, vol.26
, pp. 612-620
-
-
Khan, K.N.M.1
Venturini, C.M.2
Bunch, R.T.3
Brassard, J.A.4
Koki, A.T.5
Morris, D.L.6
-
20
-
-
0036244685
-
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents
-
Gertz BJ, Krupa D, Bolognese JA, Sperling RS, Reicin A: A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr Med Res Opin 2002;18:82-91.
-
(2002)
Curr Med Res Opin
, vol.18
, pp. 82-91
-
-
Gertz, B.J.1
Krupa, D.2
Bolognese, J.A.3
Sperling, R.S.4
Reicin, A.5
-
21
-
-
0029445164
-
Renal complications associated with use of nonsteroidal anti-inflammatory agents
-
Palmer BF: Renal complications associated with use of nonsteroidal anti-inflammatory agents. J Invest Med 1995;43:516-533.
-
(1995)
J Invest Med
, vol.43
, pp. 516-533
-
-
Palmer, B.F.1
|